Toripalimab is a recombinant, humanized anti-PD1 antibody developed by Shanghai Junshi Bioscience Co., Ltd, and was approved as a first-line treatment for locally advanced or metastatic, non-squamous NSCLC by National Medical Products Administration (NMPA) of China (27). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.